EndoPredict’s accurate low-risk assessment can help patients consider safely forgoing chemotherapy.
Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict can help accurately determine an individual patient’s 10 year risk of recurrence to help physicians identify which patients may consider can safely forgoing chemotherapy.
A Comprehensive result for confident decision-making
EndoPredict is designed for use in ER+, HER2− early-stage breast cancer patients (node-negative or node-positive (1-3 nodes), pre- or postmenopausal)
The inclusion of proliferation and hormone receptor related genes contribute to accurate assessment of early and late recurrence risk
EndoPredict was trained and validated on 10 year outcomes data, which offers powerful 10-year prognostic information for both node-negative (N0) and node-positive (N+) patients
Offers a comprehensive result—incorporating both clinical features and molecular analysis.
Identifies a large population of truly low-risk patients with excellent (average of 6% recurrence risk) 10 year outcomes with 5 years of endocrine therapy alone
Chemo-sparing benefit observed in more than 70% of node-negative breast cancer patients
Chemo-sparing benefit observed in up to one-third of node-positive breast cancer patients
EndoPredict offers a clear low- or high-risk result presented on a continuous curve
Provides an individualized test result for each patient that allows for a quick, easy to understand risk assessment